Key Insights

Highlights

Treatment Research

3 treatments under study, led by Genetically Modified Epidermolysis Bullosa Selfassembled Skin Substitute Gmebsass

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 3 (1)

Trial Status

Enrolling By Invitation1
Active Not Recruiting1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05708677Enrolling By InvitationPrimary

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

NCT07193134Phase 1/2RecruitingPrimary

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

NCT05725018Phase 3Active Not Recruiting

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Showing all 3 trials

Research Network

Common Treatments

  • Genetically Modified Epidermolysis Bullosa Selfassembled Skin Substitute Gmebsass1
  • Eb1011
  • Eb101 Surgical Application Of Rdeb Wounds1

Active Sponsors

  • Abeona Therapeutics, Inc2
  • CHU de Quebec-Universite Laval1

Top Investigators

Related Conditions

  • Recessive Dystrophic Epidermolysis Bullosa2
  • Epidermolysis Bullosa Dystrophica Recessive1
  • Epidermolysis Bullosa1

Activity Timeline